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Introduction. Laparoscopic radical nephroureterectomy (LNU) is being increasingly performed at several centers across the world.
We review oncologic outcomes after LNU procedure and the techniques for the management of distal ureter. Materials and
Methods. A comprehensive review of the literature was performed on the oncological outcomes and management of distal ureter
associated with LNU for upper tract transitional cell carcinoma (TCC). Results and Discussion.L N Uf o ru p p e rt r a c tT C Ci s
performed pure laparoscopically (LNU) or hand-assisted (HALNU). The management of the distal ureter is still debated. LNU
appears to have superior perioperative outcomes when compared to open surgery. Intermediate term oncologic outcomes after
LNU are comparable to open nephroureterectomy (ONU). Conclusions. Excision of the distal ureter and bladder cuﬀ during
nephroureterectomy remains controversial. Intermediate term oncologic outcomes for LNU compare well with ONU. Initial long-
term oncologic outcomes are encouraging. Prospective randomized comparison between LNU and open surgery is needed to
deﬁne the role of these modalities in the current context.
Copyright © 2009 A. Berger and A. Fergany. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
Upper tract TCC accounts for 5% of all urothelial tumors
[1]. It usually occurs in patients older than 60. Compared
t ob l a d d e rc a n c e r ,u p p e rt r a c tT C Ci sd i a g n o s e dm o r e
frequently at advanced stages. In most series, in almost
half the patients, tumor stages at diagnosis have been
described as pT2 or higher. Stage is the main predictor
for survival. Delay in diagnosis and treatment is related to
worse prognosis. Standard management consists of open
radical nephroureterectomy (ONU), which usually requires
one large or two separate abdominal incisions. Since LNU
was ﬁrst reported by the Washington University Group
in 1991 [2], the beneﬁts of this procedure regarding
perioperative morbidity, cosmesis, and convalescence have
been established [3–5]. Mainly, there are 2 laparoscopic
approaches: pure laparoscopic nephroureterectomy (LNU)
and hand-assisted nephroureterectomy (HALNU). Despite
theperioperativeadvantages,someoncologicalissuesremain
unclear, mainly management of the distal ureter and the role
of lymphadenectomy.
2.MaterialsandMethods
We performed an extensive National Library of Medicine
database search with no date restriction using the keywords
upper tract transitional cell carcinoma, nephroureterectomy,
and laparoscopic nephroureterectomy. Of the over 100
papers identiﬁed, 25 of each were selected for this review on
the basis of their contribution in advancing the ﬁeld with
regards to (1) evolution of concepts (2) development and
reﬁnement of techniques, and (3) intermediate oncological
outcomes.
3. Results and Discussion
3.1. Management of Distal Ureter. The management of the
distal ureter is still controversial. The open extravesical or
transvesical approach is accepted as the most oncologically
safe. However, patient factors as obesity and previous history
of pelvic surgery or radiotherapy can make ureteral excision
more diﬃcult. In 1952, McDonald et al. ﬁrst reported an
endoscopic method to handle the distal ureter [6]. In the2 Advances in Urology
laparoscopicera,manyattemptshavebeenmadetoavoidthe
open approach to the distal ureter, which is still commonly
used. Shalhav et al. [4] described the laparoscopic stapling
of the distal ureter and bladder cuﬀ and positive margins
were associated with the method. Matin et al. compared
the outcomes (median follow-up 23 months) using the two
diﬀerent techniques of en bloc excision of bladder cuﬀ:
36 patients underwent technique of cystoscopic intravesical
secured detachment of en bloc bladder cuﬀ and juxtavesical
ureter using needlescopic instruments percutaneouslly [7]
and 12 underwent laparoscopic extravesical stapling. The
stapling technique was associated with a decreased overall
survival, decreased recurrence free survival, and higher
positive surgical margin rate. Kurzer et al. (2006) evaluated
49patientsonameanfollow-upof10.6monthsandreported
their results after cystoscopic circumferential excision of the
distal ureter without primary closure of the bladder cuﬀ
with simultaneous ureteral ligation during HALNU [8]. No
c a s e so fl o c a lp e l v i co rp e r i t o n e a lr e c u r r e n c e sw e r er e p o r t e d .
Vardi et al. (2006) reported a new technique to manage
the distal ureter [9]. They proposed an en bloc excision
of the bladder cuﬀ and juxtavesical ureter during HALNU
using a ﬂexible cystoscope and a 5F electrode without
repositioning the patient. Mean follow-up was 31 months
(range 5–44) and none of the 6 patients presented with local
recurrence. Recently, Nanigan et al. (2006) reported using
robotic assistance in an attempt to decrease the technical
challenge of excision of distal ureter in 11 patients [10].
As part of the procedure, they ﬁlled the bladder with a
saline solution before opening it and aspirated all the ﬂuid
to avoid dissemination of cancer cells. In addition to the
disadvantage of increased cost, the 6-month follow-up is not
enough to evaluate local recurrence. Agarwall et al. (2008)
modiﬁed the Cleveland Clinic technique. They performed a
circumscribed incision in the ureteric oriﬁce with a bladder
cuﬀ using a Collins knife. The ureter stump was ligated
with an endoloop via cystoscope to avoid urine leak from
the upper tract. Complete excision was achieved in all 13
patients. Five patients had bladder recurrence, 2 close to the
ureteral scar [11].
Since most studies do not show any diﬀerence between
diﬀerent methods of handling the distal ureter, the best
option is to follow individual surgeon’s preference as long as
the fundamental oncological concepts are preserved: having
acompleteresectionofthedistalureterwithbladdercuﬀand
avoiding tumor spillage.
3.2. Oncological Outcomes after LNU. Laparoscopic nephr-
oureterectomy is performed utilizing the same surgical prin-
ciplesaslaparoscopicradicalnephrectomy.Atransperitoneal
or retroperitoneal approach can be chosen. Most surgeons
are familiar with the transperitoneal approach, which has
the advantage of allowing dissection of the ureter all the way
to the bladder. This is essential if endoscopic management
of the distal ureter (as previously described) is planned.
Surgeons familiar with the retroperitoneal approach to
radical nephrectomy can perform the renal part of the
operation retroperitoneally, although access to the distal
ureter is diﬃcult with this approach. This is best suited to
cases where the distal ureter will be managed through an
open approach. In either case the ureter is not divided and
left in continuity. A clip placed on the ureter will minimize
the risk of tumor seeding resulting from manipulation of the
kidney. In cases of ureteric tumors, careful attention to wide
dissection of the ureter is essential to avoid a positive margin
or entry into the ureter with tumor spillage.
Long-term follow-up after ONU is well documented in
some large series. Charbit et al. (1991) reported the ﬁrst
big follow-up series with upper tract TCC in 108 patients
[17]. Survival rates after 5 and 10 years were 67% and 65%,
respectively. Hall et al. (1998) reviewed 252 patients after
ONU (median follow-up 64 months). Recurrence occurred
in 67 (27%) patients and urothelial recurrences represented
69% of total [18]. Median time to recurrence was 12 months.
Actuarial 5-year cancer-speciﬁc survival rates by primary
tumor stage were 100% for Ta/Cis, 92% for T1, 73% for
T2, and 41% for T3. Median survival for pT4 patients
was 6 months. On multivariate analysis, tumor stage was
a signiﬁcant predictor for recurrence, whereas patient age
and stage were signiﬁcant predictors for survival. In contrast,
a multicenter study by Ozsahin et al. (1999) evaluated
126 patients with upper tract TCC (median follow-up 39
months) and reported poor oncological outcomes of ONU
[19]. In a median period of 9 months, 66% of the patients
recurred. The 5- and 10-year overall survivals were 29%
and 19%, respectively. Multivariate analysis revealed that
independent prognostic factors inﬂuencing outcome were T
staging, positive surgical margin, and tumor in the ureter.
Lower survival rates in this study may be explained by high
proportions of high grade (76%), nonorgan conﬁned disease
(59%), and positive surgical margin (26%).
Long-term follow-up studies after LNU are still sparse.
El Fettouh et al. (2002) reported the results of 116 patients
who underwent LNU on a multicenter basis with a median
follow-up of 25 months [12]. Positive margins were identi-
ﬁed in 4.5% of patients, local recurrence in 1.7%, bladder
recurrence in 24%, and mean time to recurrence was 13.9
months. Distant metastasis rate was 9%; mean time to
metastasis was 13 months. Two-year cancer-speciﬁc survival
was87%.AccordingtoTstage,2-yearcancerspeciﬁcsurvival
was89%forpT1,86%forpT2,77%forpT3,and0%forpT4.
Muntener et al. (2007) reported the outcomes of 39 patients
after LNU (median follow-up 74 months). Five-year cancer
speciﬁc survival was 68%. Tumor stage was the only factor
relatedtocancerdeathandureteraltumorwastheonlyfactor
associated with recurrence [13].
Cohorts comparing perioperative and short/intermedi-
ate oncological outcomes between ONU and LNU have been
published. Bariol et al. (2004) evaluated 25 patients who
underwent LNU and 42 who underwent ONU for TCC in
a median follow-up of 101 and 96 months, respectively [14].
Local and bladder recurrence rates were 28% (7 patients) for
LNU and 42% (15 patients) for ONU, while more ureteral
tumors were described in ONU. One and 5-year metastases-
free survivals were 80% and 72% for LNU and 87% and
82% for ONU, whileno statistical diﬀerencebetween the two
surgical treatments was found. Rouprˆ et et al. (2007) com-
pared 20 patients who underwent LNU (median follow-upAdvances in Urology 3
Table 1: LNU series and comparative studies.
Patients (n)
LNU/ONU
Median
follow-up
(mo)
Recurrence
(%)
Local
recurrence
(%)
Bladder
recurrence
(%)
Distant
metastasis
(%)
Overall
survival (%)
Cancer-
speciﬁc
survival (%)
Risk factor
associated
to survival
(%)
LNU X Series
El Fettouh 116 25 Not stated Not stated 24 9 Not stated 87 Not stated
(2002) [12] (2 year)
Muntner 39 74 46 5 Not stated 18 59 (5 year) 68 Tumor stage
(2007) [13] (5 year)
LNU versus open surgery
Bariol 58 26/22 101/96 Not stated 8/15 28/ 42 28/18 56/59 72/82 Not stated
(2004) [14] (5 year)
Rouprˆ et 46 20/ 26 68/ 78 19
(urothelial) Not stated Not stated 10/35 Not stated 90/61 Tumor stage
and grade (2006) [15] (5 year)
Manabe 224 58/166 14/ 28
(mean) 33/38 1c a s ep o r t /
2 cases Not stated 17/20 84/84 (2
year)
85/82 Tumor stage
and grade (2007) [16] (2 year)
68.5 months) to 26 who underwent ONU (median follow-
up 78 months). Recurrence occurred in 20% of cases of LNU
and53%ofONU[15].Mediantimetorecurrencewas15and
18 months, respectively. Five-year cancer-speciﬁc survival
was 90% and 61% and 5-year recurrence-free survival was
71% and 51%, respectively. Okegawa et al. (2006) compared
25 LNU (mean follow-up 24 months) and 23 ONU (mean
follow-up 29 months). In LNU and ONU groups, recurrence
rates were 20% and 17% and mean time to recurrence were
9.5 and 23.4 months [20]. Distant metastasis rate was 8%
for LNUX and 13% for ONUX. Two-year cancer-speciﬁc
survival was 91% for LNU and 89% for ONU. No signiﬁcant
diﬀerence was detected in recurrence-free survival and
cancer-speciﬁc survival. Manabe et al. (2007) evaluated 58
patients after LNU (mean follow-up 13.6 months) and 166
after ONU (mean follow-up 28 months). Bladder recurrence
was reported in 33% of patients after LNU and in 38% after
ONU [16]. Distant metastases were reported in 17% and
20% of the patients, respectively. The 2-year recurrence-free
survivals were 76% and 82%. No diﬀerence was found in
cancer-speciﬁc survival.
Some recent series report results after hand-assisted
LNU (HALNU), but oncologic outcomes are limited. Wolf
et al. evaluated 54 patients who underwent HALNU with
median follow-up of 25 months [21]. Urothelial recur-
rences occurred in 66% patients. History of bladder tumors
was associated with urothelial recurrence. Nonurothelial
recurrences were found in 25% of the patients at a mean
10.4 months follow-up. Age and grade correlated with
nonurothelial recurrence. The 2 and 3-year cancer-speciﬁc
survival were 86% and 80%, respectively. Organ-conﬁned
disease and nonorgan-conﬁned disease were associated with
a 3-year survival of 100% and 36%, respectively. High-grade
disease correlated with poorer 3-year cancer-speciﬁc sur-
vival. Chung et al. (2007) also described comparable recur-
rence free, 3-year cancer-speciﬁc and overall survivals in 39
patientsafterHALNU(medianfollow-up48months)and41
patients after ONU (median follow-up 62 months) [22].
The propensity for dissemination of high-grade TCC
is well known. An important concern with laparoscopic
approach is port site metastasis. Seven cases have been
published so far. No surgical bag was used in six cases and
the surgical bag was torn during retrieval of the specimen in
one case [22].
Recently,the importance of extended lymph node dissec-
tion for bladder cancer regarding staging and prognosis has
been established. Given the histological similarity between
bladder cancer and upper tract TCC, lymphadenectomy
should also be important for the management of upper
tract TCC. Kondo et al. (2007) evaluated 169 patients that
u n d e r w e n to p e nn e p h r o u r e t e r e c t o m yd i v i d e di n3d i ﬀer-
ent groups: complete lymphadenectomy, incomplete lym-
phadenectomy, and no lymphadenectomy [23]. Extended
lymphadenectomy improved survival in patients with pT3
stage or higher. On multivariate analysis, complete lym-
phadenectomy, T stage and grade were signiﬁcant prognostic
factors for cancer-speciﬁc survival. Brausi et al. (2007)
reported retroperitoneal lymph node dissection and T
stage as the only independent signiﬁcant prognostic factors
on overall survival [24]. Busby et al. (2006) found no
diﬀerence between ONU and LNU concerning number
of lymph nodes retrieved, median number of positive
nodes retrieved, and median density of positive nodes,
showing that lymphadenectomy can be performed in the
laparoscopic approach as adequately as in open approach
[25].
Intermediate oncological outcomesafterLNU are similar
to ONU. Series combining long follow-up and large number
of patients are lacking. Finally, to conﬁrm these previous
encouraging ﬁndings, prospective randomized trials are still
needed Table 1 summarizes the oncological outcomes after
LNU.4 Advances in Urology
4. Conclusion
Many centers worldwide are now performing LNU. Con-
temporary series have demonstrated technical feasibility and
safety. The management of distal ureter is still debated.
Although large series of 5-year oncologic data are not yet
available in the LNU literature, reports indicate that inter-
mediate and long-term oncological outcomes are similar
to ORC. Carefully designed prospective randomized trials
comparing LNU and ONU are necessary to deﬁne the role
of these modalities in the current and future management of
upper tract TCC.
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